<DOC>
	<DOCNO>NCT00506519</DOCNO>
	<brief_summary>The primary objective study explore efficacy safety ATryn® ( antithrombin alfa ) treatment disseminate intravascular coagulation ( DIC ) associate severe sepsis , administer continuous intravenous ( IV ) infusion five day .</brief_summary>
	<brief_title>Recombinant Human Antithrombin ( ATryn® ) Treatment Patients With DIC Associated With Severe Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Disseminated Intravascular Coagulation</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>Signed informed consent obtain patient his/her legally acceptable representative Severe sepsis Disseminated intravascular coagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>DIC associate severe sepsis</keyword>
</DOC>